Activity Overview
This video-based program is designed for health care professionals to explore the diagnosis and treatment of Cutaneous Lupus Erythematosus (CLE) through a unique perspective, putting the patient voice front and center. A patient will lend their expertise to this program by sharing their journey living with CLE. This online activity focuses on the burden of CLE, current management strategies, and emerging therapies for the management of patients with CLE.
Target Audience
This educational activity is directed toward Dermatologists, Rheumatologists, APPs, and other health care providers who diagnose and treat Cutaneous Lupus Erythematosus.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the clinical burden and health-related quality of life (HRQoL) impact associated with cutaneous lupus erythematosus (CLE)
- Discuss the limitations associated with current management strategies used in the treatment of CLE
- Analyze clinical trial evidence for emerging targeted therapies for CLE
Alfred Kim, MD
Washington University School of Medicine
Disclosures: Alfred Kim, MD, has no relevant financial relationships with ineligible companies.
Victoria Werth, MD
Professor of Dermatology at the Hospital of the University of Pennsylvania, Penn Medicine
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Almirall, Alpine Immune Sciences, Alumis, Architect Therapeutics, Amgen, AnaptysBio, Argenx, Arionix, AstraZeneca, Aticus, Beeline, Biogen, BMS, Boehringer Ingelheim, Cabaletta Bio, Calyx, Caribou, Crisalis, CSL Behring, Cugene, Daiichi Sanko, Dianthus Therapeutics, Duality Therapeutics, Eli Lilly, EMD Serono, Evommune, Exo Therapeutics, First Tracks Biotherapeutics, Gilead, GlycoEra, GSK, Horizon, Immunovant, Inmagene, Innovaderm, Janssen, Kyowa Kirin, Kymera, Lilly, Merck, Nektar, Novartis, Nuvig Therapeutics, Odyssey, Pfizer, Regeneron, Rome Therapeutics, Prolium, Sanofi, Takeda, UCB, Valuence, Ventus, Viela Bio, and Xencor Grant/Research Funding: Amgen, AstraZeneca, Biogen, BMS, Corbus Pharmaceuticals, CSL Behring, Gilead, Horizon, Pfizer, Priovant, Regeneron, Rome Therapeutics Royalty or Patent Benefits: U Penn owns the copyright for the CLASI, CDASI, DMOMS, CLA-IGA
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used artificial intelligence–assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.